Stock events for 10X Genomics, Inc. (TXG)
Over the past six months, 10x Genomics reported its Q3 2025 earnings on November 6, 2025, with an actual EPS of -0.219 USD, and Q4 and full-year 2025 financial results on February 12, 2026, with Q4 revenue exceeding analyst expectations at $166 million and a GAAP loss of $0.13 per share. Throughout this period, there have been news items related to partnerships and research initiatives, such as the launch of a study to advance research in blood-based diagnostics for autoimmune disease and a partnership with PharosAI to transform cancer research with AI and spatial biology. Analyst price targets have also seen adjustments, with some being raised in February 2026. The stock's 52-week range has been between a low of $6.78 and a high of $23.56.
Demand Seasonality affecting 10X Genomics, Inc.’s stock price
Seasonality analysis for 10x Genomics, Inc. (TXG) reveals recurring patterns in asset prices over a calendar year. Historically, implied volatility for TXG tends to rise the most in February, while September tends to be when implied volatility declines to its lowest levels. The company has reported robust core demand for its consumables and continued traction with its innovative spatial biology platforms. However, 10x Genomics is currently navigating a challenging macro environment, particularly concerning U.S. academic and government research funding, which has impacted revenue growth and led to cautious customer spending on capital expenditures and larger consumables projects. Despite these headwinds, the company anticipates continued growth in Chromium reaction volumes, although with expected pricing pressures. Consumables are projected to grow significantly faster than instrument revenue in the coming years, reflecting ongoing demand for advanced biological analysis tools.
Overview of 10X Genomics, Inc.’s business
10x Genomics, Inc. (TXG) is a US-based life science technology company that develops and sells instruments, consumables, and software for biological systems analysis, operating in the Healthcare sector, specifically in Health Information Services, Life Sciences Tools and Services, and Healthcare Providers & Services. The company's integrated solutions analyze biological systems with high resolution and scale, offering major product platforms like the Chromium platform for single-cell analysis, the Visium platform for spatial analysis, and the Xenium platform for in situ analysis. 10x Genomics primarily serves academic institutions, government research laboratories, biopharmaceutical companies, and biotechnology firms.
TXG’s Geographic footprint
10x Genomics operates globally across the United States, the rest of the Americas, Europe, the Middle East, Africa, China, and the Asia-Pacific region. The company utilizes a direct sales force in North America and parts of Europe, and collaborates with distribution partners in Asia and other regions.
TXG Corporate Image Assessment
In the past year, 10x Genomics has maintained a reputation as a leader in advanced genomic analysis solutions, specializing in single-cell and spatial genomics technologies. The company is recognized for its innovative approach, combining microfluidics, novel chemistry, and bioinformatics software to simplify workflows and accelerate data generation. Partnerships, such as those with PharosAI and the Cancer Research Institute, for AI-driven immuno-oncology initiatives and cancer research, have likely contributed positively to its brand image by highlighting its role in advancing scientific discovery. Despite facing financial pressures and industry-wide concerns, the company's technological prowess and focus on cutting-edge tools for genomic analysis have positioned it at the forefront of the life sciences and diagnostic tools sector.
Ownership
The ownership of 10x Genomics, Inc. (TXG) is predominantly held by institutional investors, with estimates ranging from approximately 80% to 97%. Major institutional shareholders include Vanguard Group Inc., ARK Investment Management LLC, Fmr Llc, BlackRock, Inc., Sumitomo Mitsui Trust Holdings, Inc., State Street Corp., Geode Capital Management, LLC, and Amova Asset Management Co., Ltd. Individual investors and non-institutional public entities hold a smaller portion of the shares. Company insiders, including co-founders Serge Saxonov (CEO), Ben Hindson (President/CSO), and early CTO Kevin Ness, also hold significant stakes, with Serge Saxonov being the largest individual insider.
